Candesartan and carvedilol for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin-Reference-Cited by-同舟云学术

Candesartan and carvedilol for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin

Published:2021-05-16 Issue:12 Volume:10 Page:3964-3973
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Lee Myunhee¹,Chung Woo‐Baek²^ORCID,Lee Ji‐eun³,Park Chan‐Seok⁴,Park Woo‐Chan⁵,Song Byung‐Joo⁶,Youn Ho‐Joong²

Affiliation:

1. Division of Cardiology Department of Internal Medicine Daejeon St. Mary’s HospitalCollege of MedicineThe Catholic University of Korea Seoul Korea

2. Division of Cardiology Department of Internal Medicine Seoul St. Mary’s HospitalCollege of MedicineThe Catholic University of Korea Seoul Korea

3. Division of Oncology Department of Internal Medicine Seoul St. Mary’s HospitalCollege of MedicineThe Catholic University of Korea Seoul Korea

4. Division of Cardiology Department of Internal Medicine Bucheon St. Mary’s HospitalCollege of MedicineThe Catholic University of Korea Seoul Korea

5. Division of Breast Surgery Department of Surgery Seoul St. Mary's HospitalCollege of MedicineThe Catholic University of Korea Seoul Korea

6. Division of Breast‐Thyroid surgery Department of Surgery Bucheon St. Mary's HospitalCollege of MedicineThe Catholic University of Korea Seoul Korea

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.3956

Reference35 articles.

1. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2015

2. Cardiovascular Disease Mortality Among Breast Cancer Survivors

3. Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study

4. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials

5. Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardio-Oncology’s Modern Approaches to Prevent Doxorubicin-Induced Cardiotoxicity: A Systematic Review;Cureus;2024-08-05

2. Cardio-protective effects of statins in patients undergoing anthracycline-based chemotherapy: An updated meta-analysis of randomized controlled trials;European Journal of Internal Medicine;2024-08

3. Role of Oxidative Stress and Inflammation in Doxorubicin-Induced Cardiotoxicity: A Brief Account;International Journal of Molecular Sciences;2024-07-08

4. Co-morbid intersections of cancer and cardiovascular disease and targets for natural drug action: Reprogramming of lipid metabolism;Biomedicine & Pharmacotherapy;2024-07

5. Comparing the effects of various β-blockers on cardiovascular mortality in breast cancer patients;Cardio-Oncology;2024-03-26